Trillium Asset Management LLC increased its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,808 shares of the company’s stock after buying an additional 1,937 shares during the period. Trillium Asset Management LLC’s holdings in Alkermes PLC were worth $2,771,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in shares of Alkermes PLC by 4.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 191,640 shares of the company’s stock valued at $10,651,000 after buying an additional 7,797 shares in the last quarter. Creative Planning raised its stake in shares of Alkermes PLC by 16.2% in the first quarter. Creative Planning now owns 18,012 shares of the company’s stock valued at $1,054,000 after buying an additional 2,510 shares in the last quarter. Capstone Asset Management Co. raised its stake in shares of Alkermes PLC by 8.0% in the first quarter. Capstone Asset Management Co. now owns 6,585 shares of the company’s stock valued at $385,000 after buying an additional 490 shares in the last quarter. Roanoke Asset Management Corp NY raised its stake in shares of Alkermes PLC by 17.6% in the first quarter. Roanoke Asset Management Corp NY now owns 82,591 shares of the company’s stock valued at $4,832,000 after buying an additional 12,349 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock valued at $222,000 after buying an additional 224 shares in the last quarter. 97.19% of the stock is currently owned by institutional investors and hedge funds.

Alkermes PLC (ALKS) opened at 51.60 on Wednesday. The company’s market cap is $7.93 billion. Alkermes PLC has a 12 month low of $41.93 and a 12 month high of $63.40. The firm has a 50-day moving average price of $56.35 and a 200 day moving average price of $57.24.

Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. The firm had revenue of $218.80 million for the quarter, compared to the consensus estimate of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company’s revenue was up 12.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.01) EPS. On average, equities analysts expect that Alkermes PLC will post ($0.04) earnings per share for the current year.

WARNING: “Alkermes PLC (ALKS) Position Boosted by Trillium Asset Management LLC” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/alkermes-plc-alks-position-boosted-by-trillium-asset-management-llc/1494451.html.

Several analysts recently commented on ALKS shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $62.00 price target on shares of Alkermes PLC in a research note on Monday, April 24th. J P Morgan Chase & Co set a $78.00 price target on Alkermes PLC and gave the company a “buy” rating in a research note on Thursday, April 27th. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a research note on Friday, April 28th. Credit Suisse Group set a $70.00 price target on Alkermes PLC and gave the company a “buy” rating in a research note on Friday, May 19th. Finally, ValuEngine raised Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. Alkermes PLC currently has an average rating of “Hold” and an average target price of $63.00.

In other Alkermes PLC news, SVP Michael J. Landine sold 10,000 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $57.23, for a total value of $572,300.00. Following the sale, the senior vice president now owns 167,370 shares of the company’s stock, valued at approximately $9,578,585.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard F. Pops sold 25,000 shares of the firm’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $57.42, for a total value of $1,435,500.00. Following the completion of the sale, the director now directly owns 649,137 shares in the company, valued at approximately $37,273,446.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,500 shares of company stock worth $2,866,865. Company insiders own 5.34% of the company’s stock.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.